Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
In vivo, the direct and seizure-induced neuronal cytotoxicity of kainate and AMPA is modified by the non-competitive antagonist, GYKI 52466
Autore:
Lees, GJ; Leong, W;
Indirizzi:
Univ Auckland, Sch Med, Dept Psychiat, Auckland, New Zealand Univ Auckland Auckland New Zealand Dept Psychiat, Auckland, New Zealand Univ Auckland, Sch Med, Dept Behav Sci, Auckland, New Zealand Univ Auckland Auckland New Zealand ept Behav Sci, Auckland, New Zealand Univ Auckland, Sch Med, Dept Pharmacol, Auckland, New Zealand Univ Auckland Auckland New Zealand ept Pharmacol, Auckland, New Zealand
Titolo Testata:
BRAIN RESEARCH
fascicolo: 1, volume: 890, anno: 2001,
pagine: 66 - 77
SICI:
0006-8993(20010126)890:1<66:IVTDAS>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
RECEPTOR-MEDIATED EXCITOTOXICITY; KAINIC ACID; GLUTAMATE RECEPTORS; SYNAPTIC ACTIVATION; NBQX; RAT; TOXICITY; GYKI-53655; GYKI-52466; EPILEPSY;
Keywords:
neuronal cell death; kainic acid; AMPA; non-NMDA glutamate receptor antagonist; 2,3-benzodiazepines; GYKI 52466; anticonvulsant; hippocampus;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
38
Recensione:
Indirizzi per estratti:
Indirizzo: Lees, GJ Univ Auckland, Sch Med, Dept Psychiat, Auckland, New Zealand UnivAuckland Auckland New Zealand hiat, Auckland, New Zealand
Citazione:
G.J. Lees e W. Leong, "In vivo, the direct and seizure-induced neuronal cytotoxicity of kainate and AMPA is modified by the non-competitive antagonist, GYKI 52466", BRAIN RES, 890(1), 2001, pp. 66-77

Abstract

The 2,3-benzodiazepine GYKI 52466, administered intracerebrally or systemically, was assessed for its ability to protect against the neuronal death in the brain caused by intra-hippocampal injections of the non-N-methyl-D-aspartate (NMDA) receptor agonists, kainate and L-alpha -amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA). In contrast to a previous report, a low intra-hippocampal dose of GYKI 52466 (25 nmol) did not protect against kainate toxicity, In order to achieve higher doses of GYKI 52466, solubilization in 2-hydroxypropyl-beta -cyclodextrin was used, and limited protection against AMPA, but not kainate toxicity was found. There was a commensurate reduction in seizure-related neuronal loss in the limbic regions of the brain. When diazepam was used to prevent seizures, GYKI 52466 had no effect on hippocampal neuronal loss caused by the direct toxicity of AMPA and kainate on hippocampal neurons. Systemic administration of GYKI 52466 had only a minimal effect on preventing neuronal death caused by AMPA. In vivo, GYKI 52466 is only weakly effective as a neuroprotective agent. (C) 2001 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/02/20 alle ore 08:12:10